openPR Logo
Press release

New Drug Approvals to Drive Kidney Cancer Drugs Market to USD 5.2 Billion by 2020

08-05-2016 02:10 PM CET | Health & Medicine

Press release from: iHealthcareAnalyst, Inc.

New Drug Approvals to Drive Kidney Cancer Drugs Market to USD 5.2

Kidney Cancer Drugs Market – Global Drug Types (Brand) and Clinical Pipeline Analysis and Forecast 2013-2020, estimates the global biomedical waste management services market to reach nearly USD 5.2 Billion in 2020, at a CAGR of 6.5% from 2016 to 2020 - iHealthcareAnalyst, Inc.

Visit the Kidney Cancer Drugs Market – Global Drug Types (Brand) and Clinical Pipeline Analysis and Forecast 2013-2020 report http://www.ihealthcareanalyst.com/report/kidney-cancer-drugs-market/

Renal cell carcinoma or kidney cancer drugs are often used as the first line of treatment against advanced kidney cancers. They can often shrink or slow the growth of the cancer for a time, but it doesn’t seem that any of these drugs can actually cure kidney cancer. Several targeted drugs can be used to treat advanced kidney cancer. These drugs block angiogenesis (growth of the new blood vessels that nourish cancers) or important proteins in cancer cells (called tyrosine kinases) that help them grow and survive. The global kidney cancer drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (brand) such as Afinitor (everolimus), Avastin (bevacizumab), Inlyta (axitinib), Nexavar (sorafenib), Proleukin (aldesleukin), Sutent (sunitinib), Torisel (temsirolimus), Votrient (pazopanib), clinical phase 1, 2 and 3 drugs (AGS-003, Cabozantinib, Dovitinib, Keytruda, Opdivo) pipeline analysis, and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends.

The global biomedical waste management services market is segmented as:

1. Brand Type
1.1. Afinitor (Everolimus)
1.2. Avastin (Bevacizumab)
1.3. Inlyta (Axitinib)
1.4. Nexavar (Sorafenib)
1.5. Proleukin (Aldesleukin)
1.6. Sutent (Sunitinib)
1.7. Torisel (Temsirolimus)
1.8. Votrient (Pazopanib)

2. Clinical Pipeline Analysis (Phase 3 Drugs)
2.1. AGS-003
2.2. Cabozantinib (XL184)
2.3. Dovitinib (TK1258)
2.4. Keytruda (Anti PD 1) (Pembrolizumab)
2.5. Opdivo (Nivolumab)

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profiles
4.1. Bayer AG
4.2. Bristol-Myers Squibb
4.3. F. Hoffmann-La Roche, Ltd.
4.4. GlaxoSmithKline, plc.
4.5. Merck & Co., Inc.)
4.6. Novartis AG
4.7. Pfizer, Inc.

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
http://www.ihealthcareanalyst.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Drug Approvals to Drive Kidney Cancer Drugs Market to USD 5.2 Billion by 2020 here

News-ID: 354543 • Views:

More Releases from iHealthcareAnalyst, Inc.

Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
The global market for amyotrophic lateral sclerosis devices or motor neuron disease devices anticipated to reach $19.5 billion by 2029, growing at a CAGR of 7.3% over the forecast period, driven by increasing incidence, rising geriatric population, lack of curative treatment, growing public awareness, and technological advancements in palliative care. https://www.ihealthcareanalyst.com/global-amyotrophic-lateral-sclerosis-devices-market/ Amyotrophic lateral sclerosis or Lou Gehrig's disease or motor neuron disease (MND) is characterized by progressive degeneration of the motor nerve
Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5.5 Billion by 2025
Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5. …
The global market for blood gas monitoring products is estimated to reach $5.5 billion by the end of 2025, expanding at a CAGR of 6.2% during the forecast period, supported by growing geriatric population, rising prevalence of chronic diseases, and technological advances. The global blood gas monitoring devices market research report provides market size (Revenue US$ Million 2017 to 2025), market share analysis, growth trends and forecast (CAGR%, 2019 to 2025).
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and Services Market to US$ 73.2 Billion by 2023
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and …
According to a new market research report Telemedicine Technologies and Services Market 2015-2023 published by iHealthcareAnalyst, Inc., the global computer-aided detection market to reach US$ 73.2 Billion by 2023, expanding at a CAGR of 13.5% from 2018-2023. Visit the Global Telemedicine Technologies and Services Market Analysis and Forecast 2018-2023 report at https://www.ihealthcareanalyst.com/report/telemedicine-technologies-services-market/ The global telemedicine technologies and services market newly published (updated 2018) report estimates the market size (US$ million 2015-2023)
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
The global internet pharmacies market is estimated to reach US$ 106 Billion by 2023, growing at a CAGR of 15.7% over the forecast period, driven by rising personal disposable income, lower prices, surge in internet penetration, stupendous growth of online retail market and a large number of online players entering the online healthcare product segment. The major players are in a race to increase their share in the industry by

All 5 Releases


More Releases for Drug

Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights: * Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 * Global and Regional Antibody Drug Conjugate Market Insight * Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023 * Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight * Insight On Antibody Drug Conjugates In Clinical Trials: > 550
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase